We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Barzolvolimab is an anti-KIT monoclonal antibody. 75% of ...

The investigational monoclonal antibody barzolvolimab significantly improved provocation test outcomes and reduced symptoms compared with placebo in patients with cold urticaria and symptomatic ...

Jasper Therapeutics’ monoclonal antibody briquilimab is effective at preventing mast-cell induced anaphylaxis and asthma in mice, new data suggest. In an oral presentation and two posters at the ...

BOSTON -- Treatment with an investigational anti-KIT monoclonal antibody induced clinically meaningful responses in the two most common forms of chronic inducible urticaria, a dose-ranging phase II ...

Data on new treatments for chronic spontaneous urticaria (CSU) show significant symptom reduction very early during treatment. There are multiple new drugs and mechanisms that are very promising to ...

Urticaria affects both children and adults, with chronic cases more common in women, and often presents in emergency or dermatology settings. Conditions like vasculitic urticaria, erythema multiforme, ...